Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders

Transglutaminase 2 (TG2) represents the most ubiquitous isoform belonging to the TG family, and has been implicated in the pathophysiology of basal ganglia disorders, such as Parkinson's disease and Huntington's disease. We show that ablation of TG2 in knockout mice causes a reduced activity of mitochondrial complex I associated with an increased activity of complex II in the whole forebrain and striatum. Interestingly, TG2–/– mice were protected against nigrostriatal damage induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, which is converted in vivo into the mitochondrial complex I inhibitor, 1‐methyl‐4‐phenyl‐pyridinium ion. In contrast, TG2–/– mice were more vulnerable to nigrostriatal damage induced by methamphetamine or by the complex II inhibitor, 3‐nitropropionic acid. Proteomic analysis showed that proteins involved in the mitochondrial respiratory chain, such as prohibitin and the β‐chain of ATP synthase, are substrates for TG2. These data suggest that TG2 is involved in the regulation of the respiratory chain both in physiology and pathology, contributing to set the threshold for neuronal damage in extrapyramidal disorders.

[1]  G. Corsini,et al.  Effects of Pretreatment with N‐(2‐Chloroethyl)‐N‐Ethyl‐2‐Bromobenzylamine (DSP‐4) on Methamphetamine Pharmacokinetics and Striatal Dopamine Losses , 1999, Journal of neurochemistry.

[2]  S. Cardoso,et al.  Mitochondrial function is differentially affected upon oxidative stress. , 1999, Free radical biology & medicine.

[3]  Paul R. Sanberg,et al.  3-Nitropropionic acid animal model and Huntington' s disease , 1997, Neuroscience & Biobehavioral Reviews.

[4]  S. Orrù,et al.  Proteomics Identification of Acyl-acceptor and Acyl-donor Substrates for Transglutaminase in a Human Intestinal Epithelial Cell Line , 2003, Journal of Biological Chemistry.

[5]  M. Piacentini,et al.  Ornithine decarboxylase, transglutaminase, diamine oxidase and total diamines and polyamines in maternal liver and kidney throughout rat pregnancy. , 1986, The Biochemical journal.

[6]  W. Voos,et al.  Molecular chaperones as essential mediators of mitochondrial biogenesis. , 2002, Biochimica et biophysica acta.

[7]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[8]  J. Blass,et al.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. , 2005, Biochemistry.

[9]  J. V. Van Beeumen,et al.  Mass spectrometric identification of mitochondrial oxidative phosphorylation subunits separated by two‐dimensional blue‐native polyacrylamide gel electrophoresis , 2002, Electrophoresis.

[10]  M. Wieckowski,et al.  Long‐chain fatty acids promote opening of the reconstituted mitochondrial permeability transition pore , 2000, FEBS letters.

[11]  R. Graham,et al.  Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. , 1994, Science.

[12]  D. Turnbull,et al.  Succinate-cytochrome c reductase: assessment of its value in the investigation of defects of the respiratory chain. , 1993, Biochimica et biophysica acta.

[13]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[14]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  G. Melino,et al.  `Tissue' transglutaminase in cell death: a downstream or a multifunctional upstream effector? , 1998, FEBS letters.

[16]  G. Johnson,et al.  Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ , 2000, Journal of neurochemistry.

[17]  P. Matarrese,et al.  Tissue Transglutaminase Is a Multifunctional BH3-only Protein* , 2004, Journal of Biological Chemistry.

[18]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[19]  H. Schägger Respiratory chain supercomplexes of mitochondria and bacteria. , 2002, Biochimica et biophysica acta.

[20]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[21]  M. Cookson,et al.  Mitochondria and Dopamine New Insights into Recessive Parkinsonism , 2004, Neuron.

[22]  G. Johnson,et al.  Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate‐independent mechanisms , 2005, Journal of neurochemistry.

[23]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[24]  S. O'dell,et al.  Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity , 1991, Brain Research.

[25]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[26]  H. Hefter,et al.  Is levodopa toxic? , 2004, Journal of Neurology.

[27]  Ikuko Miyazaki,et al.  Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.

[28]  G. Mardon,et al.  Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.

[29]  R. Swerdlow,et al.  Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family , 1998, Annals of neurology.

[30]  M. Beal,et al.  Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.

[31]  G. Melino,et al.  Gene Disruption of Tissue Transglutaminase , 2001, Molecular and Cellular Biology.

[32]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[33]  H. Hashimoto,et al.  Identification of amine acceptor protein substrates of transglutaminase in liver extracts: use of 5-(biotinamido) pentylamine as a probe. , 1998, Archives of biochemistry and biophysics.

[34]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[35]  J. Costentin,et al.  Correlation between (3H)dopamine specific uptake and (3H)GBR 12783 specific binding during the maturation of rat striatum. , 1989, Life sciences.

[36]  M. Beal Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[37]  Eric K. Richfield,et al.  Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .

[38]  R. Ferrante,et al.  Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.

[39]  D. D. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[40]  F. Nicoletti,et al.  Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.

[41]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[42]  M. Vila,et al.  The rotenone model of Parkinson's disease , 2003, Trends in Neurosciences.

[43]  G. Melino,et al.  ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease , 2002, Cell Death and Differentiation.

[44]  L. Grivell,et al.  Prohibitins act as a membrane‐bound chaperone for the stabilization of mitochondrial proteins , 2000, The EMBO journal.

[45]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[46]  G. Melino,et al.  Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[48]  J. Trojanowski Rotenone Neurotoxicity: A New Window on Environmental Causes of Parkinson's Disease and Related Brain Amyloidoses , 2003, Experimental Neurology.

[49]  J. Greene,et al.  Manipulation of Membrane Potential Modulates Malonate‐Induced Striatal Excitotoxicity In Vivo , 1996, Journal of neurochemistry.

[50]  L. Seiden,et al.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.

[51]  G. Corsini,et al.  Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. , 1997, The Journal of pharmacology and experimental therapeutics.

[52]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  G. Hofhaus,et al.  Use of polarography to detect respiration defects in cell cultures. , 1996, Methods in enzymology.

[54]  M. Beal,et al.  Neurochemistry and toxin models in Huntington's disease. , 1994, Current opinion in neurology.

[55]  C. Wollheim,et al.  Mitochondrial function in normal and diabetic beta-cells. , 2001, Nature.

[56]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[57]  E. Hirsch,et al.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.

[58]  F. Nicoletti,et al.  Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.

[59]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[60]  Toru Itakura,et al.  Metabolic inhibition enhances selective toxicity of l-DOPA toward mesencephalic dopamine neurons in vitro , 1997, Brain Research.

[61]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  L. Grivell,et al.  The Mitochondrial Prohibitin Complex Is Essential for Embryonic Viability and Germline Function in Caenorhabditis elegans* , 2003, Journal of Biological Chemistry.

[63]  M. Hallett,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[64]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[65]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[66]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[67]  B. Yamamoto,et al.  The effects of methamphetamine on the production of free radicals and oxidative stress. , 1998, The Journal of pharmacology and experimental therapeutics.

[68]  P. Matarrese,et al.  Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress , 2002, Journal of neurochemistry.

[69]  P. Jenner Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.

[70]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[71]  M. Murer,et al.  Levodopa in Parkinson’s Disease , 1999, Drug safety.

[72]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[73]  Francesca Cicchetti,et al.  Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease , 2005, Journal of the Neurological Sciences.